Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Incyte will pay $750 million to acquire Escient Pharmaceuticals, bringing aboard two experimental oral drugs aimed at mast-cell-driven inflammatory disease.…
Incyte said on Tuesday it would buy privately held Escient Pharmaceuticals in an all-cash deal valued at $750 million to add two experimental treatments for…
Incyte announced plans to acquire Escient Pharmaceuticals for $750 million plus net cash at close, gaining two first-in-class oral Mas-related…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Incyte (Nasdaq: INCY) acquired Escient Pharmaceuticals for $750 million plus Escient's net cash at close, announced April 23, 2024 and completed May 30, 2024. The deal brought Incyte two first-in-class oral Mas-related G protein-coupled receptor (MRGPR) antagonists: EP262 (MRGPRX2; INCB000262) for chronic urticaria and atopic dermatitis, and EP547 (MRGPRX4; INCB000547) for cholestatic and uremic pruritus -- anchoring Incyte's Inflammation & Autoimmunity pipeline. POST-CLOSE OUTCOME: on November 18, 2024, roughly six months after closing, Incyte announced both acquired lead programs had stalled. It discontinued EP547/MRGPRX4 in cholestatic pruritus after Phase 2 data did not support further development (an efficacy failure), and paused enrollment in the Phase 2 CALM-CSU study of EP262/MRGPRX2 in chronic spontaneous urticaria following in vivo preclinical toxicology findings, electing to work with the FDA on next steps while data from completed proof-of-concept studies and potential back-up molecules inform future development. The $750M outlay was upfront cash, so the impairment of both dealt-for assets materially weakened the near-term value of the acquisition.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Incyte Corporation / Escient Pharmaceuticals Inc. (this deal) | 2024 | $750M | — |
| Incyte Corporation / MacroGenics, Inc. | 2017 | $900M | 69 |
| Incyte Corporation / Vega Therapeutics, Inc. | 2026 | $2.0B | 68 |
| Incyte Corporation / Merus N.V. | 2017 | $3.0B | 35 |
| Incyte Corporation / Genesis Molecular AI, Inc. | 2026 | $1.0B | — |
| Incyte Corporation / Calithera Biosciences, Inc. | 2017 | $803M | — |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
← Browse all deals · How we score deals
More: 2024 deals · Incyte Corporation deals · Dermatology deals